FDA Inspection: ZERO Observations
Nitto Avecia Pharma Services Achieves a Flawless FDA Inspection
The FDA concluded a general inspection of the Nitto Avecia Pharma Services site from July 21 to July 25, 2025.
This routine GMP surveillance inspection evaluated the firm’s GMP compliance from the perspective of quality systems, laboratory operations, and data integrity practices.
Following the review, the site was determined to be fully compliant with industry and FDA standards, resulting in NAI with zero observations.
This achievement further highlights Nitto Avecia Pharma Services’ unwavering commitment to quality and continuous improvement.
